Cardiol Therapeutics (NASDAQ:CRDL) Upgraded by Brookline Cap M to “Strong-Buy” Rating

Brookline Cap M upgraded shares of Cardiol Therapeutics (NASDAQ:CRDL) to a strong-buy rating in a research note issued to investors on Tuesday,Zacks.com reports. Brookline Cap M also issued estimates for Cardiol Therapeutics’ Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.29) EPS.

Several other equities research analysts also recently weighed in on the company. Brookline Capital Acquisition raised Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiol Therapeutics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cardiol Therapeutics has an average rating of “Buy” and a consensus target price of $9.00.

Cardiol Therapeutics Stock Performance

CRDL traded up $0.03 during trading on Tuesday, reaching $0.99. 174,245 shares of the company’s stock were exchanged, compared to its average volume of 346,622. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.89 and a quick ratio of 3.89. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $1.59. The company’s fifty day simple moving average is $1.00 and its 200-day simple moving average is $1.09. The stock has a market capitalization of $111.10 million, a P/E ratio of -3.32 and a beta of 1.04.

Cardiol Therapeutics (NASDAQ:CRDL) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). As a group, research analysts predict that Cardiol Therapeutics will post -0.33 earnings per share for the current fiscal year.

Institutional Trading of Cardiol Therapeutics

Several institutional investors have recently bought and sold shares of the business. Boyer Financial Services Inc. purchased a new stake in shares of Cardiol Therapeutics in the fourth quarter valued at approximately $33,000. Bank of America Corp DE grew its stake in Cardiol Therapeutics by 136.2% in the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after acquiring an additional 15,255 shares during the period. Thompson Davis & CO. Inc. purchased a new stake in Cardiol Therapeutics in the 2nd quarter worth $39,000. Susquehanna International Group LLP increased its holdings in Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares in the last quarter. Finally, Sheets Smith Investment Management acquired a new position in Cardiol Therapeutics during the third quarter worth $152,000. 12.49% of the stock is owned by institutional investors and hedge funds.

More Cardiol Therapeutics News

Here are the key news stories impacting Cardiol Therapeutics this week:

• Positive Sentiment: Brookline Capital Management upgraded Cardiol to a “Strong‑Buy” and reiterated bullish coverage, which likely lifted sentiment and buying interest. Zacks upgrade note
• Positive Sentiment: Brookline’s FY2026 EPS estimate is ($0.29), modestly better than the consensus ($0.33) — the smaller projected loss can be read as incremental fundamental improvement. Brookline estimates
• Neutral Sentiment: Brookline issued a set of quarterly EPS forecasts (Q4’25–Q4’26) centered around ($0.07)–($0.08) per quarter, which largely tracks existing expectations and signals steady — not dramatic — near‑term change. Brookline estimates
• Negative Sentiment: Despite the upgrade, Cardiol remains unprofitable with negative EPS, a small market cap and limited trading volume — risks that can cap upside until clinical or commercial milestones reduce execution and funding uncertainty. Company profile & metrics

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.